SG3 Management LLC purchased a new stake in Regenxbio Inc (NASDAQ:RGNX) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,000 shares of the biotechnology company’s stock, valued at approximately $115,000.

Several other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Regenxbio by 1.1% in the first quarter. BlackRock Inc. now owns 4,877,215 shares of the biotechnology company’s stock valued at $279,514,000 after buying an additional 54,253 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Regenxbio by 10.0% in the first quarter. JPMorgan Chase & Co. now owns 1,205,445 shares of the biotechnology company’s stock valued at $69,085,000 after buying an additional 109,620 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of Regenxbio by 37.2% in the fourth quarter. Perceptive Advisors LLC now owns 645,726 shares of the biotechnology company’s stock valued at $26,894,000 after buying an additional 175,054 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Regenxbio by 47.7% in the fourth quarter. Bank of New York Mellon Corp now owns 530,908 shares of the biotechnology company’s stock valued at $22,272,000 after buying an additional 171,493 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Regenxbio by 39.9% in the first quarter. Dimensional Fund Advisors LP now owns 449,979 shares of the biotechnology company’s stock valued at $25,787,000 after buying an additional 128,266 shares in the last quarter. Institutional investors and hedge funds own 81.67% of the company’s stock.

Shares of RGNX traded down $1.15 during trading hours on Friday, reaching $48.28. 4,676 shares of the company traded hands, compared to its average volume of 616,305. The company has a quick ratio of 14.21, a current ratio of 14.21 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.72 billion, a P/E ratio of 20.25 and a beta of 0.59. Regenxbio Inc has a fifty-two week low of $38.56 and a fifty-two week high of $85.10.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.04). The company had revenue of $0.88 million for the quarter. Regenxbio had a negative net margin of 41.99% and a negative return on equity of 9.90%. As a group, equities analysts expect that Regenxbio Inc will post -2.79 EPS for the current fiscal year.

In other Regenxbio news, insider Kenneth T. Mills sold 15,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $42.99, for a total value of $644,850.00. Following the sale, the insider now directly owns 261,000 shares of the company’s stock, valued at approximately $11,220,390. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Curran Simpson sold 18,000 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $50.00, for a total value of $900,000.00. Following the completion of the sale, the senior vice president now directly owns 57,500 shares in the company, valued at $2,875,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 80,000 shares of company stock worth $4,158,370. Corporate insiders own 13.80% of the company’s stock.

A number of brokerages have recently weighed in on RGNX. Zacks Investment Research cut Regenxbio from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. BidaskClub cut Regenxbio from a “hold” rating to a “sell” rating in a research report on Thursday, May 2nd. Raymond James started coverage on Regenxbio in a research note on Thursday. They set an “outperform” rating on the stock. Chardan Capital reaffirmed a “buy” rating and set a $145.00 price objective (up previously from $127.50) on shares of Regenxbio in a research note on Wednesday, June 5th. Finally, TheStreet lowered Regenxbio from a “c” rating to a “d+” rating in a research note on Thursday, May 9th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $80.91.

COPYRIGHT VIOLATION WARNING: “SG3 Management LLC Takes Position in Regenxbio Inc (NASDAQ:RGNX)” was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/sg3-management-llc-takes-position-in-regenxbio-inc-nasdaqrgnx/3041627.html.

Regenxbio Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Read More: How To Calculate Debt-to-Equity Ratio

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.